Allogeneic stem cell transplantation for sickle cell disease
Authors:
- Ephraim J. FuchsEFEphraim J. Fuchs
- 1 November 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Hematology
- Vol. 23 (6) , 524-529
Abstract
As the safety and availability of allogeneic hematopoietic stem cell transplantation (HSCT) have improved, this procedure is becoming a viable option for nonmalignant conditions such as sickle cell disease (SCD). There are very few treatment options available for SCD, and even with optimal care SCD patients still suffer from a myriad of comorbidities to multiple organ systems and have a decreased life span. In this review, we will summarize results from trials of HSCT for children or adults with SCD using a variety of graft sources as well as conditioning and graft-versus-host disease prophylaxis regimens, and discuss the unique challenges that arise in these patients. AlloHSCT for SCD has been performed on small numbers of patients at multiple centers around the world using several different transplant platforms, and early outcomes are encouraging. Overall survival is excellent, although graft failure remains a challenge. As alloHSCT becomes safer and more widely available, the procedure should be considered for patients with severe disease phenotypes in whom the potential benefits of transplantation outweigh the complications from the disease. AlloHSCT has been shown to reverse or at least halt the progression of end-organ damage secondary to SCD. More research is needed to understand the mechanisms underlying graft failure in SCD recipients, as well as to understand the biopsychosocial underpinnings of persistent pain in the posttransplant period to maximize the benefit from the transplant procedure.Keywords
This publication has 30 references indexed in Scilit:
- The medical and ethical challenges of fertility preservation in teenage girls: a case series of sickle cell anaemia patients prior to bone marrow transplantHuman Reproduction, 2016
- Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or olderAmerican Journal of Hematology, 2016
- Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamideBlood, 2015
- Immunologic Effects of Hydroxyurea in Sickle Cell AnemiaPediatrics, 2014
- Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling GraftsTransplantation and Cellular Therapy, 2014
- Nonmyeloablative HLA-Matched Sibling Allogeneic Hematopoietic Stem Cell Transplantation for Severe Sickle Cell PhenotypeJAMA, 2014
- Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patientsBritish Journal of Haematology, 2014
- Disability Among Individuals with Sickle Cell DiseaseAmerican Journal of Preventive Medicine, 2011
- Hydroxyurea treatment for sickle cell disease: impact on haematopoietic stem cell transplantation's outcomeBone Marrow Transplantation, 2004
- Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemiaTransplantation and Cellular Therapy, 2003